Finasteride vs PTD-DBM
A side-by-side research comparison of Finasteride and PTD-DBM across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Finasteride | PTD-DBM |
|---|---|---|
| Full name | Finasteride (Propecia/Proscar) | PTD-DBM (Wnt Pathway Hair Peptide) |
| Category | Hair Growth | Hair Growth |
| Status | FDA Approved (hair loss & BPH) | Research peptide (topical) |
| Mechanism | Selectively inhibits type II 5-alpha reductase (predominant in hair follicles), reducing conversion of testosterone to dihydrotestosterone. Serum DHT decreases ~70%, scalp DHT ~40%, allowing follicle recovery. | PTD-DBM disrupts the interaction between CXXC5 and Dishevelled, releasing a natural brake on the Wnt/beta-catenin signaling pathway. Enhanced Wnt signaling promotes hair follicle neogenesis and regeneration. |
| Molecular weight | 372.54 Da | ~ (short cell-penetrating peptide) |
| Half-life | ~6-8 hours (but DHT suppression lasts 24h) | Topical (local action) |
| Bioavailability | ~80% oral | Topical (local delivery) |
| Typical dose | 1 mg (hair) or 5 mg (prostate) | Topical scalp application (research) |
| Frequency | Daily | Daily |
| Route | Oral tablet | Topical |
Finasteride reported benefits
- Halts hair loss progression (90% of men)
- Regrows hair (65% of men)
- Well-studied long-term safety
- FDA-approved
- Available generic
- Topical option available
PTD-DBM reported benefits
- Activates Wnt/beta-catenin hair pathway
- Promotes follicle neogenesis (research)
- Synergy with valproic acid
- Non-hormonal hair mechanism
Related comparisons
Research and educational reference only. Not medical advice.